Anavex Life Sciences Corp (AVXL)

[frrol]

They're really both cognitive decline diseases and both have been trial tested using the CDR Continuity of Attention test. I think the decision to use it for our PDD trial was likely because it is commonly used in PDD, and that allows us to compare with other drugs' results. That's a very common and practical (if not obviously scientific) factor biotechs use for choosing endpoints. The MMSE, ADCS, and ADSCog are often used for Alzheimer's.